Shionogi to divest Japanese pharma manufacturing operation
This article was originally published in Scrip
Shionogi has reached an agreement to sell a domestic wholly owned pharmaceutical contract manufacturing subsidiary to a Japanese private equity fund, as part of an ongoing effort to focus on its core business of developing and marketing prescription drugs.
You may also be interested in...
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.